Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)

被引：0
|
作者：
Stuve, O. [1 ]
Soelberg-Sorensen, P. [2 ]
Giovannoni, G. [3 ]
Leist, T. [4 ]
Hyvert, Y. [5 ]
Damian, D. [5 ]
Boschert, U. [5 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen, Denmark
[3] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[4] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
[5] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P690
引用
收藏
页码：335 / 336
页数：2
相关论文
共 37 条
  • [31] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Giovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [32] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    Giovannoni, G.
    SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
  • [33] Risk reduction of EDSS progression in patients with relapsing multiple sclerosis treated with cladribine tablets in the CLARITY study: post-hoc analysis including patients who went on to receive rescue therapy
    Thrower, B.
    Fox, E. J.
    Damian, D.
    Lebson, L.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 306 - 307
  • [34] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the 120-week Phase IIIb extension of the CLARITY study
    Comi, G.
    Giovannoni, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    SWISS MEDICAL WEEKLY, 2016, 146 : 77S - 77S
  • [35] Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study
    Giancarlo, Comi
    Ciovannoni, Gavin
    Cook, Stuart
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Rieckmann, Peter
    NEUROLOGY, 2016, 86
  • [36] Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg: total lymphocytes, B and T cell subsets
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 310 - 310
  • [37] CIRCULATING NATURAL-KILLER-CELLS BUT NOT CYTOTOXIC T-LYMPHOCYTES ARE REDUCED IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE-SCLEROSIS AND LITTLE CLINICAL DISABILITY AS COMPARED TO CONTROLS
    MUNSCHAUER, FE
    HARTRICH, LA
    STEWART, CC
    JACOBS, L
    JOURNAL OF NEUROIMMUNOLOGY, 1995, 62 (02) : 177 - 181
1234